EPISODE · Sep 16, 2025 · 8 MIN
Pareto Securities' Healthcare Conference: BioInvent has recently optimized its pipeline to focus on two key programs - BI-1808, the anti-TNFR2 antibody, and BI-1206, an FcγRIIB inhibitor
from BiotechTV - News · host BiotechTV
CEO Martin Welschof walks us through these two programs, which both target liquid and solid tumors. BI-1808 recently had data at EHA and will have solid tumor data later this year, while 2026 will be data rich for BI-1206.
Embed this episode
Ready to play
Pareto Securities' Healthcare Conference: BioInvent has recently optimized its pipeline to focus on two key programs - BI-1808, the anti-TNFR2 antibody, and BI-1206, an FcγRIIB inhibitor
0:00
8:38
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 8 minutes long.
When was this BiotechTV - News episode published?
This episode was published on September 16, 2025.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!